MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

NCT00326456 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

820

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: liposomal doxorubicin
DRUG: carboplatin
DRUG: paclitaxel

Sponsor

National Cancer Institute, Naples